Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | -1.74% | -2.59% | -36.52% |
May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 9.42 and 1.79 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.52% | 82.85M | - | ||
+46.19% | 55.7B | B- | ||
-6.14% | 39.57B | B | ||
+39.92% | 39.91B | A | ||
-6.65% | 28.16B | C | ||
+12.33% | 26.3B | B- | ||
-21.78% | 18.94B | B | ||
-0.35% | 12.12B | B+ | ||
+24.18% | 12.12B | B+ | ||
+28.38% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PLX Stock
- Ratings Protalix BioTherapeutics, Inc.